Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generics Office To Revise BCS Waiver Guidance Under Science Director

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of Generic Drugs is planning to revise the final guidance on biopharmaceutics classification system-based biowaivers under the leadership of Director for Science Lawrence Yu, PhD
Advertisement

Related Content

People In Brief
People In Brief
People In Brief
Bioequivalence For Modified-Release Drugs Will Need Non-Replicate Studies
Bioequivalence For Modified-Release Drugs Will Need Non-Replicate Studies
ODE V Permanent Director Bull Brings Women’s Health, Analgesics Expertise

Topics

Advertisement
UsernamePublicRestriction

Register

PS094267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel